New patent for Santen drug OMLONTI – DrugPatentWatch

Annual Drug Patent Expirations for OMLONTI

Omlonti is a drug marketed by Santen and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-two countries.

The generic ingredient in OMLONTI is omidenepag isopropyl. One supplier is listed for this compound. Additional details are available on the omidenepag isopropyl profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com